Docetaxel / P-gp/ABCB1 Cancer Research Results

docx, Docetaxel: Click to Expand ⟱
Features:
Docetaxel, (brand name Taxotere) is a chemotherapy medication used to treat breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.
Docetaxel is a microtubule-stabilizing agent (taxane). It binds β-tubulin and promotes microtubule polymerization / prevents depolymerization, causing mitotic arrest (G2/M) and downstream cell death.
Clinically important constraints:
-Neutropenia / febrile neutropenia are major dose-limiting toxicities.
-Premedication with dexamethasone is standard to reduce fluid retention and hypersensitivity reactions.
-Metabolism is mainly CYP3A4, so strong CYP3A4 inhibitors/inducers (and grapefruit) can materially change exposure.


Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Microtubule stabilization (β-tubulin) → mitotic spindle dysfunction Microtubule dynamics ↓; mitotic progression fails Also impacts normal proliferating cells P, R Core cytotoxic mechanism Taxane class MOA: stabilizes microtubules and blocks depolymerization, disrupting mitosis.
2 Mitotic arrest (G2/M checkpoint pressure) G2/M arrest ↑; proliferation ↓ Bone marrow / GI epithelium vulnerability ↑ R, G Cell-cycle blockade Mitotic arrest is the key phenotype linking microtubule disruption to cell death outcomes.
3 Intrinsic apoptosis (mitochondrial) secondary to mitotic catastrophe Apoptosis ↑ (context); caspase activation ↑ ↔ / tissue injury possible at high exposure G Death execution Cell death often occurs after prolonged mitotic arrest (mitotic catastrophe → apoptosis).
4 Neutropenia / marrow suppression (on-target toxicity) — Neutrophils ↓; febrile neutropenia risk ↑ R, G Dose-limiting toxicity Major clinical constraint; risk increases with dose and interacting drugs.
5 Hypersensitivity reactions — Hypersensitivity risk ↑ (especially early infusions) P, R Acute infusion risk Premedication is used to reduce frequency/severity of hypersensitivity reactions.
6 Fluid retention / capillary leak tendency — Fluid retention ↑ (can be severe) R, G Key non-hematologic toxicity Dexamethasone premedication is standard to reduce incidence and severity.
7 Combination leverage (sensitization with other agents) Synergy reported in multiple regimens Toxicity may ↑ depending on partner drug G Regimen-driven efficacy Docetaxel is commonly used in multi-agent protocols; outcome is regimen- and tumor-type-specific.
8 Pharmacokinetics (CYP3A4 metabolism) Exposure ↑ with strong CYP3A4 inhibitors; ↓ with inducers Exposure shifts → toxicity/efficacy shifts P, R Interaction driver Docetaxel is primarily cleared by CYP3A4; strong inhibitors can raise levels substantially.
9 Grapefruit / intestinal CYP3A4 inhibition (interaction risk) Potential exposure ↑ (context) Potential toxicity ↑ (context) P, R Diet–drug interaction Grapefruit can inhibit intestinal CYP3A4; docetaxel is a CYP3A4 substrate, so avoidance is commonly advised.
10 Parameter dependence (dose/schedule; weekly vs q3wk) Mechanism constant; tolerability differs by schedule Toxicity profile differs by schedule — Translation constraint Clinical outcomes and toxicity balance are schedule-dependent (protocol-specific).
11 ROS generation (secondary to mitotic stress) ROS ↑ (mitochondrial); lipid peroxidation ↑ (reported) Oxidative injury possible R, G Stress amplification ROS increase is secondary to mitotic arrest and mitochondrial dysfunction, not a primary redox drug effect.
12 NRF2 antioxidant response NRF2 ↑ (adaptive; reported in resistant models) Protective antioxidant upshift R, G Resistance mechanism NRF2 activation may reduce docetaxel sensitivity by increasing antioxidant capacity (GSH, NQO1, HO-1).

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (binding and immediate microtubule dynamic suppression begins)
  • R: 30 min–3 hr (mitotic checkpoint engagement; acute infusion effects)
  • G: >3 hr (mitotic catastrophe, apoptosis, tissue-level toxicities)
P-gp/ABCB1, permeability-glycoprotein: Click to Expand ⟱
Source:
Type:
P-glycoprotein (P-gp), also known as multidrug resistance protein 1 (MDR1), is a membrane protein that plays a crucial role in the transport of various substances across cellular membranes. It is part of the ATP-binding cassette (ABC) transporter family.
P-glycoprotein is often overexpressed in a variety of cancers, including breast cancer, lung cancer, leukemia, and ovarian cancer.

- The overexpression of P-glycoprotein (P-gp), is widely considered as an important reason for the MDR (multidrug resistance).

ABCB1 - ATP-Binding Cassette Subfamily B Member 1 / P-Glycoprotein

Abbreviation: ABCB1, P-gp, P-glycoprotein, MDR1

Type: ATP-dependent membrane efflux transporter / multidrug resistance protein

Function: ABCB1 encodes P-glycoprotein, an ATP-binding cassette transporter that exports a broad range of drugs, xenobiotics, lipids, and other substrates across cellular membranes. It is highly expressed in barrier tissues including the intestine, liver, kidney, placenta, and blood-brain barrier, where it limits tissue accumulation of potentially harmful compounds.

Cancer: ↑ Frequently overexpressed or functionally activated in drug-resistant tumors. Increased ABCB1 lowers intracellular concentrations of many anticancer agents by actively transporting them out of cancer cells, producing multidrug resistance and reducing chemotherapy effectiveness.

Alzheimer's Disease: ↓ Reduced ABCB1/P-glycoprotein expression or transport activity at the blood-brain barrier is associated with impaired amyloid-β clearance from the brain. Lower P-gp function correlates with increased cerebral Aβ accumulation and may contribute to Alzheimer's disease progression.
Scientific Papers found: Click to Expand⟱
96- QC,  docx,    Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, PC3
PI3K/Akt↓, Ki-67↓, BAX↑, Bcl-2↓, EpCAM↓, Twist↓, E-cadherin↑, P-gp/ABCB1↓, TumCP↓, TumCMig↓, TumCI↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis(tgid=4) ⓘ

PI3K/Akt↓, 1,  

Cell Death(tgid=5) ⓘ

BAX↑, 1,   Bcl-2↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EpCAM↓, 1,  

Migration(tgid=13) ⓘ

E-cadherin↑, 1,   Ki-67↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,   Twist↓, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

Ki-67↓, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: P-gp/ABCB1, permeability-glycoprotein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:178  Target#:232  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page